GlycoMimetics, Inc.

NASDAQ (USD): GlycoMimetics, Inc. (GLYC)

Last Price

0.324

Today's Change

+0.04 (14.08%)

Day's Change

0.28 - 0.33

Trading Volume

2,081,552

Overview

Market Cap

20 Million

Shares Outstanding

64 Million

Avg Volume

4,544,732

Avg Price (50 Days)

0.28

Avg Price (200 Days)

1.74

PE Ratio

-0.56

EPS

-0.58

Earnings Announcement

31-Jul-2024

Previous Close

0.28

Open

0.29

Day's Range

0.28 - 0.33

Year Range

0.24 - 3.53

Trading Volume

2,081,552

Price Change Highlight

1 Day Change

13.89%

5 Day Change

5.37%

1 Month Change

25.88%

3 Month Change

-82.40%

6 Month Change

-90.72%

Ytd Change

-88.09%

1 Year Change

-80.25%

3 Year Change

-84.65%

5 Year Change

-96.62%

10 Year Change

-96.22%

Max Change

-96.41%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment